DMAC News and Press, DiaMedica Therapeutics Inc. From 05/14/25

2025-05-14 11:06:10 ET More on DiaMedica Therapeutics DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript DiaMed...

2025-05-14 03:25:48 ET More on DiaMedica Therapeutics DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript DiaMedica Therapeutics GAAP EPS of -$0.60 misses by $0.01 Seeking Alpha&#x...

Conference Call and Webcast May 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Topline DM199 Preeclampsia Phase 2 Part 1A Proof of Concept Results Expected in Near Term and Phase 2 Part 1B Expected to Initiate in Q3 2025 KOL Event Scheduled for May 28, 2025 to Discuss the D...

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

2025-05-12 18:48:11 ET DiaMedica Therapeutics Inc. (DMAC) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.63%. The average open to low on the day of earnings was -5.73%. The average op...

2025-05-12 18:43:11 ET DiaMedica Therapeutics Inc. (DMAC) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in DMAC stock price following earnings has averaged ±3.17% , with a median of 2.3...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025. 2025 RBC Capital Markets Global Healthc...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13 th ...

2025-04-23 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-04-15 20:54:24 ET Summary DiaMedica Therapeutics is developing DM199 for acute ischemic stroke and preeclampsia, with promising AIS clinical trial progress and Fast Track Designation by the FDA. DM199 aims to extend the treatment window for AIS to 24 hours, potentially benefi...